AAVantgarde Bio

Advertisement

cGxPJobs Banner

AAVantgarde Secures $141 Million Series B to Advance Gene Therapies for Retinal Diseases

LONDON/MILAN, Nov. 3, 2025 — AAVantgarde Bio has raised $141 million in a Series B financing round, co-led by...

By cGxPwire Editor
November 3, 2025

Read More

FDA Grants ODD and UK CTA Clears Gene Therapy for Stargardt

MILAN, Italy, Oct. 2, 2025 — AAVantgarde Bio announced that its investigational gene therapy AAVB-039 has received Orphan Drug...

By cGxPwire Editor
October 2, 2025

Read More

Advertisement

cGxPJobs

Directory